proposed a six-gene panel (DKK3, p16, SFRP2, DKK2, NPTX2, and ppENK) to diagnose pancreatobilary cancers with sensitivity/specificity/accuracy of 77.27%/77.78%/77.50% (92). This evidence concerns the gene CDKN2A and cancer.